{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Trodelvy"},{"type":"CodeName","name":"IMMU-132"},{"type":"Abbreviation","name":"RS7-SN38"},{"type":"CASRegistryName","name":"1491917-83-9"},{"type":"Synonym","name":"hRS7-SN38 antibody drug conjugate"},{"type":"Synonym","name":"sacituzumab govitecan"}],"definition":{"html":"An antibody drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan-hziy selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. TROP2, also known as epithelial glycoprotein-1 (EGP-1), is a transmembrane calcium signal transducer that is overexpressed by a variety of human epithelial carcinomas; this antigen is involved in the regulation of cell-cell adhesion and its expression is associated with increased cancer growth, aggressiveness and metastasis.","text":"An antibody drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan-hziy selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. TROP2, also known as epithelial glycoprotein-1 (EGP-1), is a transmembrane calcium signal transducer that is overexpressed by a variety of human epithelial carcinomas; this antigen is involved in the regulation of cell-cell adhesion and its expression is associated with increased cancer growth, aggressiveness and metastasis."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/sacituzumabgovitecan-hziy","text":"Sacituzumab Govitecan-hziy"},"nciConceptId":"C102783","nciConceptName":"Sacituzumab Govitecan","termId":736415,"name":"sacituzumab govitecan-hziy","firstLetter":"s","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"sacituzumab-govitecan"},{"aliases":[{"type":"CodeName","name":"ADC MK-2870"},{"type":"CodeName","name":"SKB 264"},{"type":"CodeName","name":"SKB264"},{"type":"CodeName","name":"SKB-264"},{"type":"CodeName","name":"MK-2870"},{"type":"CodeName","name":"MK2870"},{"type":"CodeName","name":"MK 2870"},{"type":"CASRegistryName","name":"2768350-77-0"},{"type":"Synonym","name":"ADC SKB264"},{"type":"Synonym","name":"anti-TROP2 antibody-drug conjugate MK-2870"},{"type":"Synonym","name":"anti-TROP2 antibody-drug conjugate SKB264"}],"definition":{"html":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated to an as of yet undisclosed toxin, with potential antineoplastic activity. Upon administration sacituzumab tirumotecan, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake, the undisclosed toxin exerts, through an as of yet not disclosed mechanism of action, its cytotoxic effect. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors while its expression is low and/or restricted in normal, healthy tissues; its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.","text":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated to an as of yet undisclosed toxin, with potential antineoplastic activity. Upon administration sacituzumab tirumotecan, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake, the undisclosed toxin exerts, through an as of yet not disclosed mechanism of action, its cytotoxic effect. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors while its expression is low and/or restricted in normal, healthy tissues; its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival."},"drugInfoSummaryLink":null,"nciConceptId":"C166409","nciConceptName":"Sacituzumab Tirumotecan","termId":800236,"name":"sacituzumab tirumotecan","firstLetter":"s","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"sacituzumab-tirumotecan"}],"links":null}